DENVER, CO--(NewMediaWire - Apr 18, 2017) - American
Cannabis Company, Inc. (OTCQB: AMMJ)
(the "Company"), a business-to-business consulting firm and
distributor of ancillary products and services to the cannabis
industry, today announced it has secured its first retainer client
(the "Client") in the state of Louisiana. The Client, CB Medical,
LLC ("CB Medical"), is a newly formed entity that is one of the
applicants for the LSU-sponsored medical marijuana program. LSU has
indicated that it will select finalists for live presentations next
month, and then it will determine a winner in June 2017.
CB Medical retained American Cannabis Company to assist them in
designing and operating a medical marijuana program for patients in
Louisiana in partnership with the Louisiana State University
("LSU") and the Louisiana State University AgCenter ("the
AgCenter"). The medical marijuana program plans feature a
production facility in Baton Rouge, Louisiana, that will be
custom-built to produce medical marijuana for the program, complete
with an indoor cultivation center, an extraction and formulation
lab, a testing lab, and an LSU research lab. The CB Medical
production facility will showcase American Cannabis Company's
proprietary cultivation methods in two phases: phase 1 will use the
Cultivation Cube™ model, a self-contained growing system purposed
for commercial-scale growing and speed-to-market execution; and
phase 2 will apply the High Density Cultivation System™, which
maximizes potential profit and space utilized with its vertical
racking structure.
CB Medical Chairman of the Board, Dr. Kenneth Perego, MD, adds,
"We are excited to have American Cannabis Company as our long-term
partner for the LSU project. We selected them as our [cannabis]
consultant because we believe that they are the best at what they
do in the industry. In particular, we were impressed by their
proprietary cultivation methods and their past experience with
projects similar to this one. This is the right group to help us
produce pharmaceutical-grade medicine at our production
facility."
The LSU medical marijuana program is requiring bidders to
compete for one of only two medical marijuana licenses issued by
the Louisiana Department of Agriculture & Forestry to produce
pharmaceutical-grade cannabis for patients in the state. Seven (7)
companies applied for the offer and submitted SFO proposals to LSU
Procurement Services, including CB Medical. Per LSU Procurement
Services and Louisiana WAFB Channel 9 News, CB Medical is one of
the six out of seven applicants located in the state of Louisiana.
The LSU Solicitation for Offer ("SFO") was issued earlier this year
and was due on March 31.
American Cannabis Company was retained to complete the required
SFO for LSU's medical marijuana program in an effort to organize
the first legal, commercial-level cannabis operation within the
state of Louisiana. If CB Medical is awarded the offer by LSU, the
Company will work with their executive team to plan, deploy, and
oversee cultivation and marijuana-infused product manufacturing
operations. The team expects to have medical marijuana available to
Louisiana patients by the end of the year.
Terry Buffalo, CEO of American Cannabis Company, commented: "We
are excited to be working with the CB Medical group, and we would
be honored to partner with LSU and the LSU AgCenter as well. For
this program, we have assembled a world-class team of experts that
we believe are exceptionally qualified to contribute to this
project. Louisiana is a unique market because of the state's
mandate for oil-based products (i.e. no smoking or vaping), so we
had an opportunity to create some new, custom strategies to fulfill
the expected patient demand."
Earlier this week, CB Medical announced that it had partnered
with American Cannabis Company in anticipation of the LSU medical
marijuana production license. (http://www.theadvocate.com/baton_rouge/news/business/article_f88c001a-195e-11e7-af97-1b6becf5643d.html).
About American Cannabis Company, Inc.
Based in Denver, Colorado, American Cannabis Company, Inc.
offers turnkey and end-to-end solutions to existing and aspiring
participants in the cannabis industry. Their team of industry
veterans leverages hands-on experience and knowledge to provide
business planning and market assessment services, to assist with
state licensing procurement, and to create business infrastructure
and operational best practices. Since 2013, American Cannabis
Company has worked with dozens of companies that are now thriving
in the cannabis industry, many of which were awarded legal
marijuana licenses in multiple states with the assistance and
support of the Company. American Cannabis Company also owns a
portfolio of proprietary cultivation products, including: The
Satchel™, Sohum Living Soils™, The Cultivation Cube™, and The High
Density Cultivation System™. The building and development of its
brands and product suite is based on the Company's geoponics
philosophy of "combining the art and science of agriculture in
soil."
For more information, please visit:
www.americancannabisconsulting.com
www.americancannabiscompanyinc.com
www.sohumsoils.com
Forward Looking Statements
This news release contains "forward-looking statements" which
are not purely historical and may include any statements regarding
beliefs, plans, expectations or intentions regarding the future.
Such forward-looking statements include, among other things, the
development, costs and results of new business opportunities and
words such as "anticipate", "seek", "intend", "believe",
"estimate", "expect", "project", "plan", or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Actual results
could differ from those projected in any forward-looking statements
due to numerous factors. Such factors include, among others, the
inherent uncertainties associated with new projects, the future
U.S. and global economies, the impact of competition, and the
Company's reliance on existing regulations regarding the use and
development of cannabis-based drugs. These forward-looking
statements are made as of the date of this news release, and we
assume no obligation to update the forward-looking statements, or
to update the reasons why actual results could differ from those
projected in the forward-looking statements. Although we believe
that any beliefs, plans, expectations and intentions contained in
this press release are reasonable, there can be no assurance that
any such beliefs, plans, expectations or intentions will prove to
be accurate. Investors should review all the information set forth
herein and should also refer to the risk factors disclosure
outlined in our annual report on Form 10-K for the most recent
fiscal year, our quarterly reports on Form 10-Q and other periodic
reports filed from time-to-time with the Securities and Exchange
Commission. For more information, please visit www.sec.gov.